Pharma Journalist -

LEO Pharma announced that it signed an agreement to acquire U.S.-listed Timber Pharmaceuticals, Inc. Upon closing, this transaction will add an attractive late-stage asset to LEO…
Read More...

Exelixis, Inc. and Ipsen announced that the global phase 3 CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically significant improvement in…
Read More...

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that CARsgen and…
Read More...

Astellas Pharma Inc. announced the European Medicines Agency (EMA) has accepted for regulatory review the marketing authorization application (MAA) for avacincaptad pegol (ACP), an…
Read More...

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key…
Read More...

BriaCell Therapeutics Corp., a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the National Cancer…
Read More...

Bruker Corporation and PhenomeX Inc. announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per share in an all-cash transaction. The proposed…
Read More...

Ipsen announced approval by the U.S. Food and Drug Administration (FDA) of Sohonos (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic…
Read More...

Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today…
Read More...

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening…
Read More...